Cytoreductive surgery and intraoperative hyperthermic chemoperfusion for advanced ovarian carcinoma

Trevor W. Reichman, Bernadette Cracchiolo, Jahir Sama, Margarette Bryan, Jonathan Harrison, Lillian Pliner, Lawrence Harrison

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Background: Optimal cytoreductive surgery combined with intraoperative hyperthermic chemoperfusion (IHCP) is a therapy that potentially could improve survival in a select group of patients with advanced ovarian cancer. The purpose of this study was to review the results of cytoreductive surgery and IHCP for advanced ovarian cancer and to identify factors that may predict which patients maximally benefit from this aggressive treatment. Methods: Patients treated with cytoreduction followed by IHCP for ovarian cancer were identified from an IHCP database from 1/2001 through 3/2004. Several factors including resection status, peritoneal cancer index (PCI), and prior surgery were evaluated for their ability to predict survival in our cohort of patients. Results: Thirteen patients with ovarian cancer treated with cytoreductive surgery followed by IHCP were identified. The 3-year overall survival rate for all thirteen patients was 55%. The median disease-free survival was 15.4 months (3-year disease-free survival, 11%). Several factors including PCI score (<6), ability to resect all gross disease, and previous surgical exploration appeared to impart an overall survival advantage. Conclusions: The use of IHCP coupled with optimal cytoreduction is a safe and effective treatment for advanced ovarian carcinoma. However, the proper selection of patients who will benefit most from the therapy is essential for the success of the treatment.

Original languageEnglish (US)
Pages (from-to)51-56
Number of pages6
JournalJournal of Surgical Oncology
Volume90
Issue number2
DOIs
StatePublished - May 1 2005
Externally publishedYes

Fingerprint

Carcinoma
Ovarian Neoplasms
Disease-Free Survival
Survival
Therapeutics
Patient Selection
Neoplasms
Survival Rate
Databases

All Science Journal Classification (ASJC) codes

  • Surgery
  • Oncology

Cite this

Reichman, Trevor W. ; Cracchiolo, Bernadette ; Sama, Jahir ; Bryan, Margarette ; Harrison, Jonathan ; Pliner, Lillian ; Harrison, Lawrence. / Cytoreductive surgery and intraoperative hyperthermic chemoperfusion for advanced ovarian carcinoma. In: Journal of Surgical Oncology. 2005 ; Vol. 90, No. 2. pp. 51-56.
@article{a7c1d528c9aa4c3180b514189c9b01b4,
title = "Cytoreductive surgery and intraoperative hyperthermic chemoperfusion for advanced ovarian carcinoma",
abstract = "Background: Optimal cytoreductive surgery combined with intraoperative hyperthermic chemoperfusion (IHCP) is a therapy that potentially could improve survival in a select group of patients with advanced ovarian cancer. The purpose of this study was to review the results of cytoreductive surgery and IHCP for advanced ovarian cancer and to identify factors that may predict which patients maximally benefit from this aggressive treatment. Methods: Patients treated with cytoreduction followed by IHCP for ovarian cancer were identified from an IHCP database from 1/2001 through 3/2004. Several factors including resection status, peritoneal cancer index (PCI), and prior surgery were evaluated for their ability to predict survival in our cohort of patients. Results: Thirteen patients with ovarian cancer treated with cytoreductive surgery followed by IHCP were identified. The 3-year overall survival rate for all thirteen patients was 55{\%}. The median disease-free survival was 15.4 months (3-year disease-free survival, 11{\%}). Several factors including PCI score (<6), ability to resect all gross disease, and previous surgical exploration appeared to impart an overall survival advantage. Conclusions: The use of IHCP coupled with optimal cytoreduction is a safe and effective treatment for advanced ovarian carcinoma. However, the proper selection of patients who will benefit most from the therapy is essential for the success of the treatment.",
author = "Reichman, {Trevor W.} and Bernadette Cracchiolo and Jahir Sama and Margarette Bryan and Jonathan Harrison and Lillian Pliner and Lawrence Harrison",
year = "2005",
month = "5",
day = "1",
doi = "10.1002/jso.20243",
language = "English (US)",
volume = "90",
pages = "51--56",
journal = "Journal of Surgical Oncology",
issn = "0022-4790",
publisher = "Wiley-Liss Inc.",
number = "2",

}

Cytoreductive surgery and intraoperative hyperthermic chemoperfusion for advanced ovarian carcinoma. / Reichman, Trevor W.; Cracchiolo, Bernadette; Sama, Jahir; Bryan, Margarette; Harrison, Jonathan; Pliner, Lillian; Harrison, Lawrence.

In: Journal of Surgical Oncology, Vol. 90, No. 2, 01.05.2005, p. 51-56.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Cytoreductive surgery and intraoperative hyperthermic chemoperfusion for advanced ovarian carcinoma

AU - Reichman, Trevor W.

AU - Cracchiolo, Bernadette

AU - Sama, Jahir

AU - Bryan, Margarette

AU - Harrison, Jonathan

AU - Pliner, Lillian

AU - Harrison, Lawrence

PY - 2005/5/1

Y1 - 2005/5/1

N2 - Background: Optimal cytoreductive surgery combined with intraoperative hyperthermic chemoperfusion (IHCP) is a therapy that potentially could improve survival in a select group of patients with advanced ovarian cancer. The purpose of this study was to review the results of cytoreductive surgery and IHCP for advanced ovarian cancer and to identify factors that may predict which patients maximally benefit from this aggressive treatment. Methods: Patients treated with cytoreduction followed by IHCP for ovarian cancer were identified from an IHCP database from 1/2001 through 3/2004. Several factors including resection status, peritoneal cancer index (PCI), and prior surgery were evaluated for their ability to predict survival in our cohort of patients. Results: Thirteen patients with ovarian cancer treated with cytoreductive surgery followed by IHCP were identified. The 3-year overall survival rate for all thirteen patients was 55%. The median disease-free survival was 15.4 months (3-year disease-free survival, 11%). Several factors including PCI score (<6), ability to resect all gross disease, and previous surgical exploration appeared to impart an overall survival advantage. Conclusions: The use of IHCP coupled with optimal cytoreduction is a safe and effective treatment for advanced ovarian carcinoma. However, the proper selection of patients who will benefit most from the therapy is essential for the success of the treatment.

AB - Background: Optimal cytoreductive surgery combined with intraoperative hyperthermic chemoperfusion (IHCP) is a therapy that potentially could improve survival in a select group of patients with advanced ovarian cancer. The purpose of this study was to review the results of cytoreductive surgery and IHCP for advanced ovarian cancer and to identify factors that may predict which patients maximally benefit from this aggressive treatment. Methods: Patients treated with cytoreduction followed by IHCP for ovarian cancer were identified from an IHCP database from 1/2001 through 3/2004. Several factors including resection status, peritoneal cancer index (PCI), and prior surgery were evaluated for their ability to predict survival in our cohort of patients. Results: Thirteen patients with ovarian cancer treated with cytoreductive surgery followed by IHCP were identified. The 3-year overall survival rate for all thirteen patients was 55%. The median disease-free survival was 15.4 months (3-year disease-free survival, 11%). Several factors including PCI score (<6), ability to resect all gross disease, and previous surgical exploration appeared to impart an overall survival advantage. Conclusions: The use of IHCP coupled with optimal cytoreduction is a safe and effective treatment for advanced ovarian carcinoma. However, the proper selection of patients who will benefit most from the therapy is essential for the success of the treatment.

UR - http://www.scopus.com/inward/record.url?scp=17844407135&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17844407135&partnerID=8YFLogxK

U2 - 10.1002/jso.20243

DO - 10.1002/jso.20243

M3 - Article

VL - 90

SP - 51

EP - 56

JO - Journal of Surgical Oncology

JF - Journal of Surgical Oncology

SN - 0022-4790

IS - 2

ER -